Efficacy and safety of ixekizumab versus adalimumab in patients with active psoriatic arthritis and moderate-to-severe psoriasis: 52-week results from the randomised SPIRIT-H2H trial

Introduction: The randomised, open-label, assessor-blinded, parallel-group SPIRIT-H2H trial (NCT03151551) demonstrated superiority of ixekizumab over adalimumab in simultaneously achieving improvement in joint symptoms (American College of Rheumatology [ACR]50) and clearance of skin lesions (Psorias...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Kristian Reich (Autor), Lars Erik Kristensen (Autor), Saxon D. Smith (Autor), Phoebe Rich (Autor), Christophe Sapin (Autor), Soyi Liu Leage (Autor), Robert McKenzie (Autor), Christopher Schuster (Autor), Elisabeth Riedl (Autor), Melinda Gooderham (Autor)
Formato: Libro
Publicado: Mattioli1885, 2022-05-01T00:00:00Z.
Materias:
Acceso en línea:Connect to this object online.
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Internet

Connect to this object online.

3rd Floor Main Library

Detalle de Existencias desde 3rd Floor Main Library
Número de Clasificación: A1234.567
Copia 1 Disponible